Authors: Bertolini, F Mingrone, W Alietti, A Ferrucci, PF Cocorocchio, E Peccatori, F Cinieri, S Mancuso, P Corsini, C Burlini, A Zucca, E Martinelli, G

Citation: F. Bertolini et al., Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers. (vol 12, pg 987, 2001), ANN ONCOL, 12(9), 2001, pp. 1333-1333

Authors: Bertolini, F Mingrone, W Alietti, A Ferrucci, PF Cocorocchio, E Peccatori, F Cineri, S Mancuso, P Corsini, C Burlini, A Zucca, E Martinelli, G

Citation: F. Bertolini et al., Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers, ANN ONCOL, 12(7), 2001, pp. 987-990

Authors: Colombi, M Guffanti, A Alietti, A Latargia, ML Vener, C Maiolo, AT Baldini, L

Citation: M. Colombi et al., OPP-EBV-CAD regimen as salvage treatment in advanced refractory or resistant multiple myeloma, LEUK LYMPH, 40(1-2), 2000, pp. 87-94

Authors: Vener, C Guffanti, A Pomati, M Colombi, M Alietti, A La Targia, ML Bamonti-Catena, F Baldini, L

Citation: C. Vener et al., Soluble cytokine levels correlate with the activity and clinical stage of Hodgkin's disease at diagnosis, LEUK LYMPH, 37(3-4), 2000, pp. 333-339